The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy
Open accessAbstract
Key Points: Preinfusion dim CD19 expression and rare CD19– events in B-ALL do not affect relapses or responses to CD19-directed CAR T-cells. Prior blinatumomab treatment increases the rate of failure to achieve MRD– remission and CD19– MRD and relapse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Self-citationChimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · cited 3×
“Patient characteristics Consecutive patients (n 5 166) with relapsed/refractory B-ALL who received initial CD19-redirected CAR T-cell therapy from 2012 through 2017 were analyzed.(1,5) These included 91 males and 75 females, with a median age of 12 years (range, 1-29).”
BackgroundMethodResultSelf-citationLee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Ruella, M., Xu, J., Barrett, D. M., Fraietta, J. A., Reich, T. J., Ambrose, D. E., Klichinsky, M., Shestova, O., Patel, P. R., Kulikovskaya, I., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0201-9 · Cited by 659 · cited 6×
“NGS analysis of antibody VH gene rearrangements in 6 patients (HP-15, HP-19, HP-74, HP-78, HP-84, and HP-152) revealed that the identical dominant clone was present in the pre-CAR and CD19 recurrence samples (Figure 5C-D; supplemental Data).(7) The CD19 MRD/relapse group also includes 3 B-ALL (HP-78, HP-144, and HP-15…”
BackgroundResultInfluentialSelf-citationCD19 CAR T cell product and disease attributes predict leukemia remission durability
Finney, O. C., Brakke, H., Rawlings-Rhea, S., Hicks, R., Doolittle, D., Lopez, M., Futrell, B., Orentas, R. J., Li, D., Gardner, R., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125423 · Cited by 346
Cited by
Hayden, P. J., Roddie, C., Bader, P., Basak, G. W., Bonig, H., Bonini, C., Chabannon, C., Ciceri, F., Corbacioglu, S., Ellard, R., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2021.12.003 · Cited by 442
Snowden, J. A., Sánchez-Ortega, I., Corbacioglu, S., Basak, G. W., Chabannon, C., de la Camara, R., Dolstra, H., Duarte, R. F., Glass, B., Greco, R., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01691-w · Cited by 379
Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL
Shah, N. N., Lee, D. W., Yates, B., Yuan, C. M., Shalabi, H., Martin, S., Wolters, P. L., Steinberg, S. M., Baker, E. H., Delbrook, C. P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02262 · Cited by 354
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
Amini, L., Silbert, S. K., Maude, S. L., Nastoupil, L. J., Ramos, C. A., Brentjens, R. J., Sauter, C. S., Shah, N. N., & Abou-el-Enein, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00607-3 · Cited by 335
Self-citationPlaks, V., Rossi, J. M., Chou, J., Wang, L., Poddar, S., Han, G., Wang, Z., Kuang, S.-Q., Chu, F., Davis, R. E., et al. (2021) · Blood · doi:10.1182/blood.2021010930 · Cited by 199
Metadata
- Authors
- Pillai, V., Muralidharan, K., Meng, W., Bagashev, A., Oldridge, D. A., Rosenthal, J., Van Arnam, J., Melenhorst, J. J., Mohan, D., DiNofia, A. M., Luo, M., Cherian, S., Fromm, J. R., Wertheim, G., Thomas-Tikhonenko, A., Paessler, M., June, C. H., Luning Prak, E. T., Bhoj, V. G., Grupp, S. A., Maude, S. L., & Rheingold, S. R.
- Venue
- Blood Advances
- Publisher
- American Society of Hematology
- Published
- 2019-11-18
- Volume
- 3
- Issue
- 22
- Pages
- 3539-3549
- ISSN
- 2473-9529 (ISSN-L)
- 2473-9537
- OpenAlex
- W2985081230
- Cited by
- 206
- References
- 5
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. https://app.cochat.ai/papers/10.1182/bloodadvances.2019000692
- The paper
- Pillai, V., Muralidharan, K., Meng, W., Bagashev, A., Oldridge, D. A., Rosenthal, J., Van Arnam, J., Melenhorst, J. J., Mohan, D., DiNofia, A. M., Luo, M., Cherian, S., Fromm, J. R., Wertheim, G., Thomas-Tikhonenko, A., Paessler, M., June, C. H., Luning Prak, E. T., Bhoj, V. G., . . . Rheingold, S. R. (2019). CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Advances. https://doi.org/10.1182/bloodadvances.2019000692
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.